In preclinical models, pharmacological inhibition of de novo purine synthesis was efficacious as a monotherapy against MTAP-deficient GBM and reduced the percentage of GBM cells positive for CD133, a glioma stem cell marker [4,12]. Here, PROM1 is linked to glioblastoma.